As CAR T cells move into earlier lines of therapy for multiple myeloma, Vinay Prasad MD MPH discusses some of the lessons learned from trials of these agents to date: nature.com/articles/s4157…

Young boy dies in trial for Pfizer Duchenne gene therapy

$pfe $srpt statnews.com/2024/05/07/duc…

It's even worse than this. Cochrane shows no reduction in all cause mortality in pooled analysis of all trials at any age. Welch papers show massive over diagnosis. Astonishing we spend so much money on something so unproven.

CART-T cells in multiple myeloma: lessons learned nature.com/articles/s4157… via Vinay Prasad MD MPH

It's really problematic we allow drug companies to use faulty research and clearly erroneous data to push their products. These numbers are derived from bad science. (Way too high)

Just out in Nature Reviews Drug Discovery
7 lessons @ FDA ODAC CAR-T myeloma
#1 No OS benefit, Increased early death from CAR-T
No problem
#2 Control arms prohibit the best regimens (no DKd)
#3 cilta-cel banned & ida-cel misunderstands X over
#4 No reported QoL
🧵
rdcu.be/dHb4B

Theo Baker The Atlantic I’m with Vinay Prasad MD MPH on the Theo Baker–Stanford prof dust-up.

drvinayprasad.com/p/stanford-pro…

Improving Your Critical Appraisal Skills: Diagnostic Tests (part 2)
sensible-med.com/p/improving-yo… via Adam Cifu

Speaking only to vaccine-associated myocarditis…

I think the CDC has themselves to blame for their poor performance over the last 4 years, it's hard to increase funding for an organization that did such a bad job, in almost every way possible. Including numerous basic numerical errors.
drvinayprasad.com/p/the-cdc-is-a…

As a case study in how medical sciences can go wrong there is no better scenario than the response covid 19 and few better than Dr Prasad to break it down.

- vaccine safety problems
- vaccine recommendation problems
- public health problems

All carefully explained and…

An excellent deep dive into the specifics of the paper's statistical methodology by Vinay Prasad.
Put simply: the signal you see isn't the total signal in existence. It's undercounting.
When the benefit is low or questionable, even low risk makes benefit-risk ratio unacceptable

I perform a deep analysis of this paper, in press now

drvinayprasad.com/p/covid19-vacc…

Check out our latest post on drugdevletter.com
Timothée Olivier, MD Vinay Prasad MD MPH
'While most discussions of the shortage centered on supply chain and patient care issues, we delved into the financial ramifications of substituting cisplatin with costly alternative treatments.'

Just out Timothée Olivier, MD and Alyson Haslam and I show how Quality of Life reporting depends on *completion rate* of forms.
Completion rate is so poor (or imbalanced) in many modern RCTs that QoL is entirely unreliable
VKPrasadLab
sciencedirect.com/science/articl…

I’m not an oncologist and a lot these studies are intimidating due to the hard names of drugs. But. If I’m diagnosed with cancer, and a doc recommends a Rx, I’m googling it along with “Vinay Prasad”. Incredibly important work for patients and society. Kudos John Arnold

Out today in EJC, with Alyson Haslam and Vinay Prasad MD MPH ❗️👇

We explored the reliability of quality of life (QoL) results when a lot of patients quit a trial.

authors.elsevier.com/sd/article/S09…
1/6
🧵